The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a potentially life-extending treatment for a rare form of lung cancer.
Around 2,000 people in England have pleural mesothelioma and it is estimated that over 600 people – including armed forces veterans and people who were previously exposed to asbestos before it was banned in 1999 – could benefit from the new treatment.
Opdivo – also known as nivolumab – in combination with Yervoy – known generically as ipilimumab – has been recommended in NICE’s draft final appraisal document as a first-line treatment option for untreated, unresectable malignant pleural mesothelioma in adults. Both treatments are made by Bristol Myers Squibb…
